← ANALYST RATINGS · TIPRANKS
Lucid Diagnostics (LUCD): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $2.75, the highest $3.00, the lowest $2.50. The average is +475.3% from the last price of $0.48.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $0.52 → $0.51−1.0% | Hold | +6.7% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $0.50 → $0.50−1.4% | Hold | +4.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $0.50 | Hold | +5.4% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $0.50 → $0.50−1.0% | Hold | +4.4% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $0.53 → $0.50−6.2% | Hold | +4.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $0.51 → $0.50−2.5% | Hold | +4.0% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $3.00 | Buy | +527.6% | Reiterated | 01.10.26on TipRanks 12:26 | −15.8%next day −1.8% · 5 days +1.2% | ↗ |
| Anthony Vendetti★★★★★★★★★★#12408 · hits 27% · avg −19.8% | Maxim Group | $2.00 | Buy | +318.4% | Reiterated | 23.09.26on TipRanks 13:55 | −5.3%next day +0.1% · 5 days −9.7% | ↗ |
| Edward Woo★★★★★★★★★★#12401 · hits 30% · avg −17.6% | Ascendiant | $9.25 → $9.50+2.7% | Buy | +1,887.4% | Reiterated | 26.08.26on TipRanks Aug 27 07:50 | −4.0%next day +0.8% · 5 days +2.1% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $2.50 | Buy | +423.0% | Reiterated | 17.08.26on TipRanks 06:46 | +1.5%next day +1.9% · 5 days +3.5% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $3.00 | Buy | +527.6% | Reiterated | 15.05.26on TipRanks May 14 07:15 | −0.8%next day −1.6% · 5 days −1.2% | ↗ |
| Ross Osborn★★★★★★★★★★#11870 · hits 30% · avg −6.3% | Cantor Fitzgerald | $3.00 | Buy | +527.6% | Reiterated | 18.11.25on TipRanks Nov 19 10:00 | −1.0%next day −3.2% · 5 days +1.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Lucid Diagnostics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $4.25 at a price of $0.75 (+465.9%); now: $4.25 at $0.48 (+789.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 4 | 3 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.06 (from $-0.06 to $-0.05). Last quarter: $-0.06.
Sales
Next quarter’s sales estimate — $2M (from $1M to $2M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Lucid Diagnostics
- CEO: Lishan Aklog
- Employees: 82
- 360 Madison Avenue, New York City, NY, 10017, US
- www.luciddx.com
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Data from the stock’s TipRanks forecast page, read 14 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗